Sinteza 2-(1H-indol-3-il)acetil-N-(supstituiranih fenil)hidrazinkarbotioamida i srodnih heterocikličkih spojeva te procjena njihovog antikonvulzivnog djelovanja i toksičnosti by NADEEM SIDDIQUI et al.
In recent years, indole derivatives have acquired conspicuous significance due to
their wide spectrum of biological activities. The anticonvulsant drug design is based on
the presumption (1) that for the activity in maximal electroshock seizure (MES) evalua-
tion, at least one phenyl or similar aromatic group in close proximity to a two electron
donor atom is required. For activity in pentylenetetrazole (PTZ) evaluation, an alkyl group
close to a two electron donor atom is needed.
Several five-membered aromatic systems such as triazoles, oxadiazoles and thiadia-
zoles having three heteroatoms at symmetrical positions have been evaluated for their
anticonvulsant activity (2, 3). New 3-aryl/alkylimino-indol-2-ones were synthesized and
screened for their anticonvulsant and anti-inflammatory activities. Compounds having
1-naphthyl and 4-chlorophenyl substituents were most potent compounds of the series
(4). A series of 3-aryl/alkylimino-indol-2-ones were synthesized and screened for anti-
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A series of new 5-(1H-indol-3-yl)methyl-4-(substituted
aryl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones (4a-g), 5-(1H-
-indol-3-yl)methyl-N-(substituted aryl)-1,3,4-oxadiazol-
-2-amines (5a-g) and 5-(1H-indol-3-yl)methyl-N-(substi-
tuted aryl)-1,3,4-thiadiazol-2-amines (6a-g) were prepared
by treating 2-(1H-indol-3-yl)acetyl-N-(substituted phen-
yl)hydrazine carbothioamides (3a-g) with suitable rea-
gents. All the newly synthesized compounds were scree-
ned for their anticonvulsant activity in the MES model
and were compared with the standard drugs phenytoin
sodium and carbamazepine. Out of the twenty-one com-
pounds studied, 4b, 4e, 4f, 5b, 5d, 5g, 6b, 6d and 6e sho-
wed comparable MES activity to phenytoin and carbama-
zepine after 0.5 h. Compound 5b showed to be more po-
tent than carbamazepine after 4 h. Compounds 4a, 4c, 4d,
5a, 5c, 5e, 5f, 6f and 6g showed lower neurotoxicity than
phenytoin.
Keywords: indoles, triazoles, thiadiazoles, oxadiazoles, anti-
convulsants, neurotoxicity
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convulsant activity by electroshock and chemoshock methods. The compound having a
naphthyl moiety showed 100% protection (5).
As part of the programme on the synthesis of bi-heterocyclic compounds containing
indole as one of the heterocyclic units, we undertook the synthesis of heterocycles whe-
rein the two potentially active moieties are present together and to explore the anticon-
vulsant activity associated with these nuclei.
EXPERIMENTAL
The chemicals and solvents used for the experimental work were commercially pro-
cured from E. Merck, India, CDH, s.d. Fine Chem. and Qualigens, India. Silica gel G
(160–120 mm) used for analytical chromatography (TLC) was obtained from E. Merck.
Melting points were determined in an open glass capillary using a Kjeldahl flask
containing paraffin and are uncorrected. The proton magnetic resonance spectra (1H NMR)
were recorded on a Bruker 300 MHz instrument (Bruker, Germany) in DMSO-d6/CDCl3
using tetramethylsilane [(CH3)4Si] as internal standard. Chemical shifts (d) are expressed
in ppm. The infrared spectra of compounds were recorded in KBr on a Bio-Rad FTIR
(Browser Morner, USA) spectrometer. Elemental analyses were performed on a Perkin-
-Elmer model 240c analyzer (Perkin Elmer, USA). The physicochemical and spectral data
of the compounds are listed in Tables I and II, respectively.
Syntheses
Ethyl-(1H-indol-3-yl) acetate (1). – Indole-3-acetic acid (0.05 mol) was dissolved in abso-
lute ethanol (10 mL). Conc. H2SO4 (1 mL) was added and the reaction mixture was reflu-
xed for 28 h. Reaction mixture gave on processing ethyl ester (1). The solid obtained was
washed with sodium bicarbonate solution (10%, 50 mL) and crystallized from methanol.
2-(1H-indol-3-yl)acetohydrazide (2). – Hydrazine hydrate (10 mL) was placed in a round
bottom flask, and compound 1 (0.004 mol) was added. Contents were diluted with a suf-
ficient quantity of dry ethanol till clear solution was obtained and the reaction mixture
was refluxed for 20–22 h. After completion of the reaction, ethanol was distilled off till a
small volume was left. On cooling, crystals of acid hydrazides (2) were formed and were
filtered and recrystallized from ethanol.
2-(1H-indol-3-yl-acetyl)-N-(substituted phenyl)hydrazinecarbothioamides (3a-g). – A mix-
ture of 2-(1H-indol-3-yl)acetohydrazide (2, 0.01 mol, 2 g) and substituted phenylisothio-
cyanates (0.01 mol) in 20 mL of absolute ethanol was refluxed for 5–6 h. After comple-
tion of the reaction the reaction, mixture was concentrated and kept overnight at room
temperature. The needle shaped crystals thus obtained were purified by repeated wash-
ing with petroleum ether (6).
5-(1H-indol-3-yl methyl)-4-(substituted aryl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones (4a-g).
– A mixture of substituted hydrazinecarbothioamides (3, 0.004 mol, 1.23 g) and 30 mL of
2%. NaOH solution was refluxed for 6 h. After completion of the reaction, the reaction
mixture was filtered and the filtrate was neutralized with conc. HCl dropwise till pH
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was adjusted to 7. The mixture was kept aside for a few minutes. The distinctive precipi-
tate thus obtained was filtered, washed with water, and recrystallized from a mixture of
ethanol/water (80:20) (6).
5-(1H-indol-3-yl)methyl-N-(substituted aryl)-1,3,4-oxadiazol-2-amines (5a-g). – A solu-
tion of substituted hydrazinecarbothioamides (3, 0.004 mol, 1.23 g) and sodium hydrox-
ide (5 mol L–1, 2 mL) in 25 mL of absolute ethanol was cooled under continuous stirring
for 30 min. To this mixture, iodine in KI (5%) was added dropwise till the color of iodine
persisted at room temperature. After that the mixture was refluxed for 2 h. After com-
pletion of the reaction, the reaction mixture was poured onto crushed ice. The solid thus
obtained was washed with sodium thiosulphate solution and recrystallized from abso-
lute ethanol (6).
5-(1H-indol-3-yl)methyl-N-(substituted aryl)-1,3,4-thiadiazol-2-amines (6a-g). – Concentrated
sulphuric acid (5 mL) was placed in a conical flask, and substituted hydrazinecarbothio-
amides (3, 0.004 mol, 1.23 g) were added in small portions over a period of 2 h under stir-
ring while maintaining the temperature at about 0–5 °C. When the reaction was completed,
the mixture was poured onto crushed ice. Precipitated solid thus obtained was filtered, wa-
shed with water, dried at room temperature and recrystallized from absolute ethanol (6).
Pharmacology
Anticonvulsant screening. – Albino mice (Swiss, 18–25 g) of either sex were used as
experimental animals. The animals were kept at room temperature (25–30 °C) on an ade-
quate diet and allowed free access to food and water except during the short time they
were removed from the cages for testing. All the experimental protocols were carried
out with the permission from Institutional Animal Ethics Committee. Animals were ob-
tained from the Central Animal House Facility, Hamdard University, New Delhi, India.
Initial anticonvulsant evaluations of the test compounds were undertaken by fol-
lowing the anticonvulsant drug development (ADD) program protocol (7, 8). Albino mice
were stimulated through corneal electrodes to 50 mA current at a pulse of 60 Hz applied
for 0.25 s. Animals were previously given the test drug i.p. Abolition of the hind limb
tonic extension spasm was recorded as the anticonvulsant activity. The test compounds
were suspended in a 0.5% methyl cellulose-water mixture or in polyethylene glycol (PEG).
In preliminary screening, each compound was administered through an i.p. injection at
three dose levels (30, 100 and 300 mg kg–1 body mass) and the anticonvulsant activity
was assessed after 0.5 h and 4 h intervals of administration (9). The anticonvulsant effi-
cacy was evaluated by the maximal electroshock-induced seizure (MES) and data are pre-
sented in Table III.
Neurotoxicity screening. – Activity of the drug interfering with motor coordination
was checked by the rotorod test (10). In that test, mice were trained to stay on the knur-
led plastic rod. Rod was rotated by 10 rotations min–1 and its diameter was 3.2 cm. Nor-
mal mice could maintain equilibrium on the rotating rod for long periods of time. The
test compounds were injected i.p. at doses of 30, 100, 300 mg kg–1 body mass and tested
at the time of the peak drug effect to measure the effect of the drug.
Neurotoxicity of compounds was indicated by the inability of the animal to main-
tain equilibrium on the rod for at least one minute in each of the three trials. Mice lost
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their balance due to their skeletal muscle relaxation effect of the drug. The dose at which
50% of the animals were disabled to balance and fell off the rotating rod was determined.
RESULTS AND DISCUSSION
The synthetic pathway is presented in Scheme 1. All the title compounds were
newly synthesized and their structures were confirmed on the basis of IR and 1H NMR
spectra (Tables I and II).
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6f 3-CH3 C18H16N4S
(320.41)














a Solvent for crystallization – ethanol.
b Melting point of the compounds at their decomposition.












d log P was calculated from absorbance data using chloroform/phosphate buffer at 28 °C.
e Elemental analysis for C, H, N were within ± 0.4% of the theoretical value.
Table II. Spectral characterization of synthesized compounds
Compd. FT-IR (KBr, cm–1) 1H NMR (DMSO-d6, d ppm)
4a 3671 (NH str.), 3396 (Ar-CH), 2361
(CH2), 1641 (C=N), 1563 (C=C),
1224 (C=S), 1010 (N-N)
10.64 (s, 1H, NH triazole), 7.96 (s, 1H, NH indole),
6.83-7.52 (m, 9H, Ar-H), 6.47 (s, 1H, CH indole),
4.14 (s, 2H, CH2)
4b 3883 (NH str.), 3461 (Ar-CH), 2351
(CH2), 1639 (C=N), 1551 (C=C),
1082 (N-N), 797 (C-Cl)
10.53 (s, 1H, NH triazole), 8.33 (s, 1H, NH indole),
6.70-7.52 (m, 8H, Ar-H), 6.35 (s, 1H, CH indole),
3.71 (s, 2H, CH2)
4c 3634 (NH str.), 3463 (Ar-CH), 2394
(CH2), 1638 (C=N), 1551 (C=C), 1446
(C=S), 1388 (COCH3), 1100 (N-N)
10.56 (s, 1H, NH triazole), 8.33 (s, 1H, NH indole),
6.51–8.04 (m, 8H, Ar-H), 6.51 (s, 1H, CH indole),
3.84 (s, 3H, OCH3), 1.19 (s, 2H, CH2)
4d 3678 (NH Str.), 3489 (Ar-CH),
2215(CH2), 1645 (C=N), 1496 (C=C),
1483 (C=S), 1359 (COCH3), 1083
(N-N)
10.48 (s, 1H, NH triazole), 8.29 (s, 1H, NH indole),
6.44–8.39 (m, 8H, Ar-H), 6.47 (s, 1H, CH indole),
3.61 (s, 3H, OCH3), 1.23 (s, 2H, CH2)
4e 3580 (NH str.), 3417 (Ar-CH), 2349
(CH3), 1643 (C=N), 1550 (C=C),
1449 (C=S), 1024 (N-N)
10.53 (s, 1H, NH triazole), 7.53 (s, 1H, NH indole),
6.81–7.33 (m, 8H, Ar-H), 6.35 (s, 1H, CH indole),
4.14 (s, 2H, CH2), 3.71 (s, 3H, CH3)
4f 3556 (NH str.), 3401 (Ar-CH), 2398
(CH3), 1601 (C=N), 1567 (C=C),
1487 (C=S), 1032 (N-N)
10.51 (s, 1H, NH triazole), 7.48 (s, 1H, NH indole),
6.78–7.41 (m, 8H, Ar-H), 6.41 (s, 1H, CH indole),
4.23 (s, 2H, CH2), 3.75 (s, 3H, CH3)
4g 3573 (NH str.), 3415 (Ar-CH), 2382
(CH3), 1634 (C=N), 1543 (C=C),
1476 (C=S), 1056 (N-N)
10.49 (s, 1H, NH triazole), 7.50 (s, 1H, NH indole),
6.84–7.65 (m, 8H, Ar-H), 6.29 (s, 1H, CH indole),
4.27 (s, 2H, CH2), 3.63 (s, 3H, CH3)
5a 3556 (NH str.), 3261 (Ar-CH), 2356
(CH2), 1642 (C=N), 1568 (C=C),
1093 (N-N), 1009 (C-O-C)
10.83 (s,1H, NH), 8.70 (s, 1H, NH indole),
6.54–7.46 (m, 9H, Ar-H), 5.66 (s, 1H, CH indole),
4.13 (s, 2H, CH2)
5b 3660 (NH str.), 3426 (Ar-CH), 2348
(CH2), 1665 (C=N), 1638 (C=C), 1386
(N-N), 1089 (C-O-C), 746 (C-Cl)
8.93 (s,1H, NH), 8.24 (s, 1H, NH indole),
6.96–8.22 (m, 8H, Ar-H), 6.96 (s, 1H, CH indole),
2.72 (s, 2H, CH2)
5c 3745 (NH str.), 3447 (Ar-CH), 2366
(CH2), 1646 (C=N), 1517 (COCH3),
1096 (C-O-C), 793 (N-N)
10.70 (s, 1H, NH), 8.36 (s, 1H, NH indole),
6.83–7.52 (m, 8H, Ar-H), 6.54 (s, 1H, CH indole),
3.85 (s, 3H, OCH3), 3.77 (s, 2H, CH2)
The anticonvulsant activity and neurotoxicity of all compounds were examined us-
ing reported procedures (7–10). The anticonvulsant evaluation of compounds 4a-g, 5a-g
and 6a-g in mice at 30, 100 and 300 mg kg–1 by i.p. MES (maximal electroshock seizure)
and NT (neurotoxicity screening) are summarized in Table III together with the litera-
ture data on the drugs used as standards, phenytoin and carbamazepine.
Compounds 4b, 4e, 4f, 5b, 5d, 5g, 6b, 6d and 6e exhibited fifty percent or more pro-
tection at a dose of 30 mg kg–1 after 0.5 h and have shown activity comparable to pheny-
toin and carbamazepine. Among these compounds, 4b, 4e, 4f, 5d, 5g, 6d and 6e were
also active after 4 h at a dose of 100 mg kg–1 body mass. This shows the rapid onset and
long duration of action of these compounds at a comparatively low dose. Compound 5b
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5d 3751 (NH str.), 3456 (Ar-CH), 2398
(CH2), 1676 (C=N), 1534 (COCH3),
1112 (C-O-C), 780 (N-N)
10.74 (s, 1H, NH), 8.41 (s, 1H, NH indole),
6.78–7.76 (m, 8H, Ar-H), 6.49 (s, 1H, CH indole),
3.81 (s, 3H, OCH3), 3.60 (s, 2H, CH2)
5e 3671 (NH str.), 3423 (Ar-CH), 2367
(CH2), 1640 (C=N), 1563 (C=C),
1230 (N-N), 1014 (C-O-C)
10.69 (s, 1H, NH), 8.31 (s, 1H, NH indole),
6.82–7.75 (m, 8H, Ar-H), 6.35 (s, 1H, CH indole),
3.02 (s, 3H, CH3), 2.72 (s, 2H, CH2)
5f 3676 (NH str.), 3414 (Ar-CH), 2356
(CH2), 1667 (C=N), 1565 (C=C),
1245 (N-N), 1023 (C-O-C)
10.74 (s, 1H, NH), 8.46 (s, 1H, NH indole),
6.76–7.87 (m, 8H, Ar-H), 6.23 (s, 1H, CH indole),
3.15 (s, 3H, CH3), 2.63 (s, 2H, CH2)
5g 3692 (NH str.), 3456 (Ar-CH), 2360
(CH2), 1630 (C=N), 1565 (C=C),
1243 (N-N), 1002 (C-O-C)
10.54 (s, 1H, NH), 8.27 (s, 1H, NH indole),
6.78–7.62 (m, 8H, Ar-H), 6.20 (s, 1H, CH indole),
3.23 (s, 3H, CH3), 2.69 (s, 2H, CH2)
6a 3568 (NH str.), 3211 (Ar-CH), 2340
(CH2), 1630 (C=N), 1594 (C=C),
1032 (N-N), 604 (C-S-C)
10.22 (s, 1H, NH), 9.52 (s, 1H, NH indole),
6.66–8.70 (m, 9H, Ar-H), 6.66 (s, 1H, CH indole),
4.25 (s, 2H, CH2)
6b 3694 (NH str.), 2921 (Ar-CH), 2283
(CH2), 1585 (C=N), 1503 (C=C),
943 (N-N), 743 (C-S-C), 699 (C-Cl)
10.22 (s, 1H, NH), 8.31 (s, 1H, NH indole),
6.50–8.91 (m, 8H, Ar-H), 6.50 (s, 1H, CH indole),
4.03 (s, 2H, CH2)
6c 3519 (NH str.), 3296 (Ar-CH), 2365
(CH2), 1649 (C=N), 1598 (C=C), 1149
(COCH3), 1030 (N-N), 605 (C-S-C)
11.07 (s, 1H, NH), 8.41 (s, 1H, NH indole),
7.08–7.52 (m, 8H, Ar-H), 5.34 (s, 1H, CH indole),
4.39 (s, 2H, CH2), 3.81 (s, 3H, OCH3)
6d 3523 (NH str.), 3287 (Ar-CH), 2350
(CH2), 1640 (C=N), 1587 (C=C), 1154
(COCH3), 1046 (N-N), 615 (C-S-C)
11.13 (s, 1H, NH), 8.23 (s, 1H, NH indole),
7.16–7.67 (m, 8H, Ar-H), 5.12 (s, 1H, CH indole),
4.43 (s, 2H, CH2), 3.78 (s, 3H, OCH3)
6e 3633 (NH str.), 3263 (Ar-CH), 2921
(CH3), 2386 (CH2), 1614 (C=N),
1585 (C=C), 1030 (N-N), 616 (C-S-C)
11.02 (s, 1H, NH), 9.23 (s, 1H, NH indole),
7.84 (s, 1H, CH indole), 6.98–7.81 (m, 8H, Ar-H),
4.33 (s, 2H, CH2), 1.51 (s, 3H, CH3)
6f 3627 (NH str.), 3255 (Ar-CH), 2943
(CH3), 2378 (CH2), 1623 (C=N),
1598 (C=C), 1043 (N-N), 632 (C-S-C)
11.15 (s, 1H, NH), 9.29 (s, 1H, NH indole),
7.81 (s, 1H, CH indole), 6.82–7.98 (m, 8H, Ar-H),
4.45 (s, 2H, CH2), 1.43 (s, 3H, CH3)
6g 3643 (NH str.), 3271 (Ar-CH), 2934
(CH3), 2390 (CH2), 1623 (C=N),
1590 (C=C), 1043 (N-N), 665 (C-S-C)
11.23 (s, 1H, NH), 9.34 (s, 1H, NH indole),
7.98 (s, 1H, CH indole), 6.78–7.89 (m, 8H, Ar-H),
4.25 (s, 2H, CH2), 1.65 (s, 3H, CH3)
s – singlet, m – multiplet, str – stretching
was found to be the most active in the series that showed protection against seizures
both after 0.5 h and 4 h at 30 mg kg–1 body mass.
Compunds 4a, 4d, 4g, 5a, 5c, 6a, 6c and 6g showed protection at a dose of 100 mg
kg–1 body mass after 0.5 h. These compounds were also active after 4 h but at a higher
dose, 300 mg kg–1 body mass, except compounds 4d and 6a which were active after 4 h
at the same dose, 100 mg kg–1 body mass. This shows the ability of these compounds to
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Table III. Anticonvulsant activity and minimal motor impairment (mg kg–1) of synthesized compounds
Compd.
No.
Intraperitoneal injection in mice
MES screen after injection (h)a Neurotoxicity screen after injection (h)a
0.5 4 0.5 4
Control – – – –
4a 100 300 300 –
4b 30 100 30 –
4c 300 300 300 –
4d 100 100 300 –
4e 30 100 100 300
4f 30 100 100 300
4g 100 300 100 100
5a 100 300 300 300
5b 30 30 30 300
5c 100 300 300 –
5d 30 100 100 300
5e – 300 300 300
5f – 300 300 300
5g 30 100 100 300
6a 100 100 30 100
6b 30 300 100 300
6c 100 300 100 300
6d 30 100 100 300
6e 30 100 30 100
6f 300 – 300 300
6g 100 300 300 300
Phenytoinb 30 30 100 100
Carbamazepineb 30 100 300 300
MES – maximal electroshock seizure
a Doses of 30, 100 and 300 mg kg–1 were administered i.p. Test compounds were suspended in 0.5% methylcellu-
lose/water mixture or in polyethylene glycol (PEG). Figures in the table indicate the minimum dose with bio-
activity demonstrated in half or more of the mice. The dash (–) indicates the absence of activity at maximum dose
administered (300 mg kg–1).
b Data from references 11 and 12.
prevent spreading of seizures. All the remaining compounds, except 5e and 5f, were ac-
tive at 300 mg kg–1.
In the rotorod test, compounds 4a, 4c, 4d, 5a, 5c, 5e, 5f, 6f and 6g showed neuro-
toxicity comparable to carbamazepine and were less toxic than phenytoin.
Compounds with the electron withdrawing chloro substituent at the ortho position
to the amino group led to considerable increase in the activity but were relatively more
toxic. The presence of a bulkier electron donating methoxy group at para position of the
amino group resulted in an increase in activity. This may be due to the increase in lipo-
philicity of the compound. The effect of the methyl group was found to be different in
the three groups of compounds. In the case of triazole derivatives, the activity was as
follows: o ~ m > p, with no effect on toxicity. In the case of oxadiazole derivatives, only
p-substituted compound was active, and in thiadiazole derivatives it followed the order
of o ~ p > m.
CONCLUSIONS
Indole based heterocyclic derivatives were found to have encouraging anticonvul-
sant activity. Some are promising and need to be further investigated to get better agents.
These may act as lead molecules for the future.
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S A @ E T A K
Sinteza 2-(1H-indol-3-il)acetil-N-(supstituiranih fenil)hidrazinkarbotioamida i
srodnih heterocikli~kih spojeva te procjena njihovog antikonvulzivnog djelovanja
i toksi~nosti
NADEEM SIDDIQUI, M. SHAMSHER ALAM i WAQUAR AHSAN
Reakcijom 2-(1H-indol-3-il)acetil-N-(supstituiranih fenil)hidrazinkarbotioamida (3a-g) s
odgovaraju}im reaktantom sintetizirana je serija novih 5-(1H-indol-3-il)metil-4-(supsti-
tuiranih aril)-2,4-dihidro-3H-1,2,4-triazol-3-tiona (4a-g), 5-(1H-indol-3-yl)metil-N-(sup-
stituiranih aril)-1,3,4-oksadiazol-2-amina (5a-g) i 5-(1H-indol-3-il)metil-N-(supstituiranih
aril)-1,3,4-tiadiazol-2-amina (6a-g). Ispitano je antikonvulzivno djelovanje sintetizi- ra-
nih spojeva na MES modelu i uspore|eno s djelovanjem fenitoin natrija i karbamaze-
pina. Spojevi 4b, 4e, 4f, 5b, 5d, 5g, 6b, 6d i 6e pokazali su MES djelovanje usporedivo s
djelovanjem fenitoina i karbamazepina nakon 0,5 h, dok je spoj 5b nakon 4 sata imao
sna`nije djelovanje od karbamazepina. Osim toga, spojevi 4a, 4c, 4d, 5a, 5c, 5e, 5f, 6f i 6g
su manje neurotoksi~ni od fenitoina.
Klju~ne rije~i: indoli, triazoli, tiadiazoli, oksadiazoli, antikonvulzivi, neurotoksi~nost
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University)
New Delhi-110062, India
454
N. Siddiqui et al.: Synthesis, anticonvulsant and toxicity evaluation of 2-(1H-indol-3-yl)acetyl-N-(substituted phenyl)hydrazine
carbothioamides and their related heterocyclic derivatives, Acta Pharm. 58 (2008) 445–454.
